Delving into the Latest Updates on Sodium Iodide I-131 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

131Iカプセル, Iodotope

+ [4]

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Thyroid CancerContrast agents

Inactive Indication-

Originator Organization

GE Healthcare, Inc.

Active Organization

Jubilant DraxImage, Inc.

FUJIFILM Toyama Chemical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (02 Aug 1990),

Contrast agents

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaINa

InChIKeyFVAUCKIRQBBSSJ-LAIFMVDKSA-M

CAS Registry7790-26-3

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer.
This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).

Start Date01 Mar 2023

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT04952493

/ Unknown statusPhase 2IIT

The Efficacy and Safety of Anlotinib Hydrochloride or Penpulimab In Combination With RAI in Patients With Local Advanced or Metastatic Differentiated Thyroid Cancer: A Randomized, Open-label, Exploratory Clinical Trial

The purpose of this study is to assess the efficacy and safety of anlotinib in combination with I-131 in locally advanced/metastatic differentiated thyroid cancer. Anlotinib may stop the growth of tumor cells and improve iodine uptake.

Start Date15 Sep 2021

Sponsor / Collaborator

Peking Union Medical College Hospital

[+1]

100 Clinical Results associated with Sodium Iodide I-131

Login to view more data

100 Translational Medicine associated with Sodium Iodide I-131

Login to view more data

100 Patents (Medical) associated with Sodium Iodide I-131

Login to view more data

388

Literatures (Medical) associated with Sodium Iodide I-131

01 Sep 2024·Bioorganic Chemistry

Novel 131-iodine labeled and ultrasound-responsive nitric oxide and reactive oxygen species controlled released nanoplatform for synergistic sonodynamic/nitric oxide/chemodynamic/radionuclide therapy

Article

Author: Wu, Zhifang ; Li, Sijin ; Liu, Wen ; Zhang, Huaiping ; Geng, Jiamei ; Zhang, Chengwu ; Zhao, Huanhuan ; Yu, Qiang ; Diao, Haipeng ; Ma, Sufang ; Li, Leyan

Nitric oxide (NO) and reactive oxygen species (ROS) embody excellent potential in cancer therapy. However, as a small molecule, their targeted delivery and precise, controllable release are urgently needed to achieve accurate cancer therapy. In this paper, a novel US-responsive bifunctional molecule (SD) and hyaluronic acid-modified MnO₂ nanocarrier was developed, and a US-responsive NO and ROS controlled released nanoplatform was constructed. US can trigger SD to release ROS and NO simultaneously at the tumor site. Thus, SD served as acoustic sensitizer for sonodynamic therapy and NO donor for gas therapy. In the tumor microenvironment, the MnO₂ nanocarrier can effectively deplete the highly expressed GSH, and the released Mn²⁺ can make H₂O₂ to produce ^.OH by Fenton-like reaction, which exhibited a strong chemodynamic effect. The high concentration of ROS and NO in cancer cell can induce cancer cell apoptosis ultimately. In addition, toxic ONOO^-, which was generated by the reaction of NO and ROS, can effectively cause mitochondrial dysfunction, which induced the apoptosis of tumor cells. The ¹³¹I was labeled on the nanoplatform, which exhibited internal radiation therapy for tumor therapy. In -vitro and -vivo experiments showed that the nanoplatform has enhanced biocompatibility, and efficient anti-tumor potential, and it achieves synergistic sonodynamic/NO/chemodynamic/radionuclide therapy for cancer.

01 Sep 2024·Journal of Clinical & Translational Endocrinology

Cross-section of thyroidology and nephrology: Literature review and key points for clinicians

Review

Author: Chehade, Joe M ; Belal, Heiba F

There are several key points clinicians should consider when managing patients with overlapping thyroid and renal disease. Patients who are euthyroid and have chronic kidney disease (CKD) may physiologically have normal-high thyroid stimulating hormone (TSH), low free thyroxine (FT4), low free triiodothyronine (FT3) and normal-low reverse triiodothyronine (rT3). Untreated subclinical and primary hypothyroidism among patients with (CKD) is associated with reversible progression of renal failure. Supplementing these (CKD) patientswith levothyroxine can delay the progression of renal failure and prevent end stage renal disease (ESRD). Untreated hyperthyroidism increases the glomerular filtration rate (GFR) by 18 to 25%. Thus, the management of hyperthyroidism may unmask patients with undiagnosed CKD. There is no dosage adjustment required for methimazole among patients with CKD. However, methimazole may be eliminated during hemodialysis (HD) by around 30 to 40%. Patients with papillary thyroid cancer and ESRD may have higher rates of aggressive characteristics. Patients with CKD and ESRD undergoing radioiodine I-131 treatment for thyroid cancer are at increased risk of prolonged radiation transmission risk due to decreased iodine urinary excretion. Additionally, the optimal dosing and timing of radioiodine I-131 therapy amongst patients with ESRD and thyroid cancer requires further research. The use dosimetry studies and multidisciplinary coordination among nuclear medicine, nephrology and endocrinology is recommended for these patients.

01 Jul 2024·Heliyon

Life-threatening amiodarone-induced thyrotoxicosis – Personalized approach to radical treatment

Article

Author: Żabicka, Katarzyna ; Kostecka-Matyja, Marta ; Partyński, Bartosz ; Buziak-Bereza, Monika ; Hubalewska-Dydejczyk, Alicja ; Sokołowski, Grzegorz ; Opalińska, Marta ; Pantofliński, Jacek ; Sowa-Staszczak, Anna ; Kieć-Klimczak, Małgorzata ; Gilis-Januszewska, Aleksandra ; Pach, Dorota

ObjectiveAmiodarone is an iodine-rich molecule and an effective antiarrhythmic drug. It is a first-line treatment for patients with life-threatening ventricular arrhythmias and for prevention in patients at high risk. The use of amiodarone may cause serious adverse effects such as pharmacotherapy-resistant, life-threatening amiodarone-induced thyrotoxicosis (AIT)leading to rapid deterioration of the patient's condition.According to the European Thyroid Association (ETA) guidelines, emergency thyroidectomy is the first-line treatment option in these cases. ; however, is not always feasible in the clinical setting due to the high anesthetic risk.We aimed to assess the clinical course and results of urgent thyroidectomy and 131-I therapy in patients with severe AIT with worsening of cardiac status.MethodsRetrospective analysis of the clinical course and outcomes of life-threatening AIT refractory to pharmacotherapy in patients hospitalized at a tertiary endocrinology center between 2014 and 2022.ResultsAn electronic database search identified 75 patients hospitalized for severe AIT. At the time of AIT diagnosis, median Thyroid-stimulating hormone (TSH) concentration was 0.001 mIU/L (range 0.001-0.35), fT4 63.2 pmol/L (range 9.0 - >100), and fT3 10.2 pmol/L (range 3.8-49.3). All patients received optimal conservative treatment. Among them, 20 required urgent radical therapy due to worsening arrhythmias and/or AIT-related heart failure. In this group, 6 patients died before any radical treatment was applied, 6 underwent total thyroidectomy, while 8 patients were successfully treated with 131-I (in 6 cases after rhTSH stimulation). The median dose of 131-I used for the therapy was 784MBq (range 627-860). The decision to treat with 131-I despite low but detectable 131-I uptake (median value 6 %) was made in cases of significant contraindications to anesthesia due to refractory ventricular arrhythmias, exacerbation of severe heart failure unresponsive to cardiac treatment, myocardial infarction during AIT course, massive pulmonary embolism.ConclusionThe decision regarding the optimal time and type of radical treatment of AIT refractory to pharmacotherapy is critical for patients management and should not be delayed. Urgent therapy with 131-I may be an effective therapeutic option in patients who are unsuitable for thyroidectomy due to the high risk of anesthesia.

100 Deals associated with Sodium Iodide I-131

Login to view more data